Clinical Trials Logo

Clinical Trial Summary

To the investigators knowledge there are no studies in the literature evaluating the effect of Dexamethasone administration on patients undergoing outpatient vaginal prolapse surgeries.


Clinical Trial Description

The lifetime risk of undergoing surgical intervention for pelvic organ prolapse (POP) is estimated to be 10% and it is projected that from 2010 to 2050, the number of surgeries for POP will rise by 47.2%, from 166,000 to 245,970. In 1980, accounting for the rising costs of health care, congress approved Medicare to reimburse procedures performed at outpatient and ambulatory surgery centers. This led to an increasing number of stress incontinence (SUI) procedures being performed in the ambulatory setting from 34,968 in 1996 to 105,656 in 2006. However, the number of ambulatory POP surgeries decreased in the same time period. This was possibly due to the increase in the mean age of women undergoing ambulatory procedures for POP and SUI during that time periods. At the investigator's institution has performed outpatient surgeries for POP and SUI for the past 3 years. Patients have tolerated same day surgery with minimal complications. In the investigator's previous prospective study assessing satisfaction after outpatient surgeries for POP and SUI, patients had a decreased quality of recovery at 48 hours compared to baseline. The investigators also recognized that nausea and pain control could have been better addressed. Unpleasant postoperative nausea and vomiting, pain control, return to normal voiding and return of bowel function can influence the quality of recovery (QOR) from surgery. Postoperative nausea and vomiting (PONV) and pain management are particularly troubling for the patients. This might also delay discharge and prolong convalescence from the surgery. Several safe interventions have been assessed in the literature for alleviating PONV, pain and recovery from laparoscopic gynecologic surgery. Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hamper the production and release of anti-inflammatory mediators, thereby decreasing postoperative nausea, emesis, pain perception and Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe. Pauls et al in their recent study randomized patients undergoing vaginal prolapse surgery to receive Dexamethasone and noted a decrease in PONV and reduced requirement of a rescue antiemetic. Their model involved patients with overnight stay and the results may not be applicable to our population. They also noted that women who received Dexamethasone preoperatively were more likely to pass the voiding trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03338400
Study type Interventional
Source The Cleveland Clinic
Contact
Status Completed
Phase Phase 2
Start date May 1, 2017
Completion date August 21, 2018

See also
  Status Clinical Trial Phase
Completed NCT01217190 - Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets Phase 1/Phase 2
Recruiting NCT06302673 - The Role Of Laserpuncture For Prevention Of Nausea And Vomiting Post Strabismus Surgery With General Anesthesia In Adult Patients N/A
Recruiting NCT04563494 - The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain Phase 4
Completed NCT00108095 - A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting Phase 2
Not yet recruiting NCT05426278 - The Effect Of Intraoperative Forced Air Warmer Use, On Postoperative Nausea And Vomiting N/A
Withdrawn NCT04954365 - Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
Not yet recruiting NCT06356623 - A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
Withdrawn NCT05016076 - Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial N/A
Not yet recruiting NCT04899817 - Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy Phase 4
Recruiting NCT05875077 - Propofol Versus Dexmedetomidine on the Incidence of Postoperative Nausea and Vomiting N/A
Completed NCT05692245 - Dexamethasone vs Ondansetron After Cesarean Delivery Phase 4
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Completed NCT00326248 - Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women Phase 3
Completed NCT00334152 - Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women Phase 3
Recruiting NCT03586817 - PALONOSETRON X FOSAPREPITANT IN PONV Phase 4
Not yet recruiting NCT06357234 - Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Phase 2
Completed NCT03045133 - QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Phase 4
Not yet recruiting NCT06410365 - Impact of Intrathecal vs Intravenous Dexmedetomidine Phase 4
Recruiting NCT05474001 - Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia N/A
Enrolling by invitation NCT05439798 - Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting Phase 3